Payment overview · 2025
General Payments
$2,979.60
112 reported records · 15 companies
Healthcare provider profile · identity verified
Srikanth Damaraju, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · CORPUS CHRISTI, TX · NPI 1790785442
Verified facts
What the public records show
CMS Open Payments records show Srikanth Damaraju, M.D. received $2,979.60 in general payments during 2025 across 112 reported records.
Medtronic, Inc. accounted for 67.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 680 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYNDAMAX as an associated drug or biological on 1880 records involving 1527 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vyndamax by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$2,003.39 | 67.2% | 65 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $137.22 | 4.6% | 9 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $130.72 | 4.4% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $103.88 | 3.5% | 5 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $89.64 | 3.0% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $79.30 | 2.7% | 4 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $69.48 | 2.3% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $67.79 | 2.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $62.74 | 2.1% | 3 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $62.44 | 2.1% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $60.16 | 2.0% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $35.95 | 1.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.16 | 1.1% | 2 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $21.55 | 0.7% | 1 | 2025 |
| LANTHEUS MEDICAL IMAGING, INC. | Unresolved — no canonical attribution shown | $21.18 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,945.97 | 106 |
| Travel and Lodging | $1,033.63 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVERA MRI XT DR SURESCAN Normalized: evera mri xt dr surescan |
Device | Medtronic, Inc. | $1,113.38 | 9 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $240.09 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $130.72 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $116.96 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $116.96 | 8 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $102.24 | 8 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $89.64 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $79.30 | 4 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $71.58 | 5 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $70.61 | 3 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $69.48 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $69.48 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $62.74 | 3 | 2025 |
Source payment records
|
|||||
| Coronary Other Normalized: coronary other |
Device | Philips North America LLC | $60.16 | 1 | 2025 |
Source payment records
|
|||||
| FFRANGIO Normalized: ffrangio |
Device | Medtronic, Inc. | $53.66 | 4 | 2025 |
Source payment records
|
|||||
| VALIANT CAPTIVIA Normalized: valiant captivia |
Device | Medtronic, Inc. | $49.16 | 3 | 2025 |
Source payment records
|
|||||
| EXCLUDER Conformable AAA Endoprosthesis with Active Control Normalized: excluder conformable aaa endoprosthesis with active control |
Device | W. L. Gore & Associates, Inc. | $47.46 | 2 | 2025 |
Source payment records
|
|||||
| TOURGUIDE STEERABLE SHEATH Normalized: tourguide steerable sheath |
Device | Medtronic, Inc. | $43.59 | 3 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $43.41 | 4 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $35.95 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.16 | 2 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $33.92 | 3 | 2025 |
Source payment records
|
|||||
| TELESCOPE Normalized: telescope |
Device | Medtronic, Inc. | $33.36 | 2 | 2025 |
Source payment records
|
|||||
| VISI-PRO Normalized: visi pro |
Device | Medtronic, Inc. | $31.69 | 1 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| TURBOHAWK Normalized: turbohawk |
Device | Medtronic, Inc. | $21.45 | 1 | 2025 |
Source payment records
|
|||||
| TRAILBLAZER Normalized: trailblazer |
Device | Medtronic, Inc. | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| DEFINITY Normalized: definity |
Drug | LANTHEUS MEDICAL IMAGING, INC. | $21.18 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| PROTEGE RX Normalized: protege rx |
Device | Medtronic, Inc. | $19.97 | 2 | 2025 |
Source payment records
|
|||||
| CHOCOLATE PTA BALLOON CATHETER Normalized: chocolate pta balloon catheter |
Device | Medtronic, Inc. | $19.53 | 2 | 2025 |
Source payment records
|
|||||
| HELI-FX ENDOANCHOR SYSTEM Normalized: heli fx endoanchor system |
Device | Medtronic, Inc. | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| VIANCE Normalized: viance |
Device | Medtronic, Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $16.20 | 2 | 2025 |
Source payment records
|
|||||
| GORE CARDIOFORM Septal Occluder Normalized: gore cardioform septal occluder |
Device | W. L. Gore & Associates, Inc. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $12.26 | 1 | 2025 |
Source payment records
|
|||||
| PACIFIC XTREME Normalized: pacific xtreme |
Device | Medtronic, Inc. | $11.05 | 1 | 2025 |
Source payment records
|
|||||
| STEERANT Normalized: steerant |
Device | Medtronic, Inc. | $6.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 680 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
32 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
117 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
680 | 154 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | VYNDAMAX open payments reported associated product |
CMS Open Payments — General Payments 1880 supporting records · 1527 recipient NPIs · example record 1228795749 |
Vyndamax · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 1090 | 356 |
| Eliquis | Apixaban | 680 | 154 |
| Atorvastatin Calcium | Atorvastatin Calcium | 620 | 196 |
| Clopidogrel | Clopidogrel Bisulfate | 599 | 226 |
| Furosemide | Furosemide | 479 | 186 |
| Potassium Chloride | Potassium Chloride | 363 | 136 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 344 | 111 |
| Losartan Potassium | Losartan Potassium | 317 | 101 |
| Carvedilol | Carvedilol | 284 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 260 | 86 |
| Lisinopril | Lisinopril | 232 | 82 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 231 | 83 |
| Spironolactone | Spironolactone | 196 | 60 |
| Nitroglycerin | Nitroglycerin | 182 | 106 |
| Metoprolol Tartrate | Metoprolol Tartrate | 154 | 57 |
| Xarelto | Rivaroxaban | 136 | 37 |
| Entresto | Sacubitril/Valsartan | 117 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 87 | 26 |
| Nifedipine Er | Nifedipine | 86 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 83 | 28 |
| Warfarin Sodium | Warfarin Sodium | 81 | 23 |
| Repatha Sureclick | Evolocumab | 80 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 25 |
| Simvastatin | Simvastatin | 71 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 69 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 62 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 19 |
| Telmisartan | Telmisartan | 60 | 16 |
| Ezetimibe | Ezetimibe | 59 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 19 |
| Jardiance | Empagliflozin | 53 | 13 |
| Valsartan | Valsartan | 52 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 17 |
| Sotalol | Sotalol Hcl | 46 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 45 | 16 |
| Chlorthalidone | Chlorthalidone | 39 | 15 |
| Flecainide Acetate | Flecainide Acetate | 38 | suppressed |
| Praluent Pen | Alirocumab | 37 | suppressed |
| Atenolol | Atenolol | 33 | 11 |
| Brilinta | Ticagrelor | 32 | 14 |
| Nitroglycerin Patch | Nitroglycerin | 32 | suppressed |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Jantoven | Warfarin Sodium | 27 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Cilostazol | Cilostazol | 24 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Klor-Con 10 | Potassium Chloride | 18 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 18 | 11 |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Omeprazole | Omeprazole | 14 | suppressed |
| Vyndamax | Tafamidis | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Klor-Con 8 | Potassium Chloride | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,979.60 · 112 records | Medtronic, Inc. | ABRE, AURORA EV-ICD MRI SURESCAN, Barostim Neo System, CHOCOLATE PTA BALLOON CATHETER, COREVALVE EVOLUT R, Coronary Other, DEFINITY, DIAMONDBACK PERIPHERAL, ELIQUIS, ENDOCROSS Device, ENDURANT IIS, ESPRIT, EVERA MRI XT DR SURESCAN, EXCLUDER Conformable AAA Endoprosthesis with Active Control, FARXIGA, FFRANGIO, GORE CARDIOFORM Septal Occluder, HAWKONE, HELI-FX ENDOANCHOR SYSTEM, JARDIANCE, LEQVIO, LINQ II, LifeVest, MICRA, NURTEC ODT, PACIFIC XTREME, PAXLOVID, PERCLOSE PROSTYLE, PROTEGE RX, REPATHA, STEERANT, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TELESCOPE, TOURGUIDE STEERABLE SHEATH, TRAILBLAZER, TURBOHAWK, Torus Stent Graft System, VALIANT CAPTIVIA, VIANCE, VISI-PRO, VYNDAQEL | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error